Newly developed compounds such as the P2Y2 agonist denufusol (cystic fibrosis) and the P2X7 antagonist AZD 9056 (Crohn’s disease) demonstrate the therapeutic potential of agonists and antagonists of purinergic receptors in various human diseases [78]. This evidence concerns the gene P2RY2 and Crohn disease.